Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Rhea-AI Summary

Adagene (Nasdaq: ADAG), a pioneer in antibody-based therapies, has announced its upcoming presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The presentation, titled 'ADG126 SAFEbody®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance', is scheduled for 11:30 AM - 11:50 AM Eastern Time at the Sheraton Boston Hotel.

The summit brings together pharmaceutical companies, biotech firms, academia, and investors focused on advancing cancer immunotherapy treatments. The presentation will be held in Track 2, Back Bay Ballroom AB, with slides becoming available on the company's website afterward.

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11^th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025.

The summit, designed for all-size pharma/biotech companies, academia and investors seeking to enable a patient’s immune ​​​​system to eradicate cancer, provides the opportunity to hear directly from science and business stakeholders on the latest data impacting the field of immuno-oncology.

Immuno-Oncology 360⁰ Summit

• Title: ADG126 SAFEbody^®: Targeting CTLA-4+ Tregs to Overcome MSS CRC Resistance
• Date: Wednesday, March 26, 2025
• Time: 11:30 AM - 11:50 AM Eastern Time
• Onsite Location: Sheraton Boston Hotel, Track 2, Back Bay Ballroom AB

Following the presentation, the slides will also be available on the Presentations page of the Company’s website.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody^® precision masking technology in multiple approaches at the vanguard of science.

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.

For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.

SAFEbody^® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Safe Harbor Statement
This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene’s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Investor Contacts:

Raymond Tam
Raymond_tam@adagene.com

Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com

FAQ

When and where is Adagene (ADAG) presenting at the Immuno-Oncology 360⁰ Summit?

Adagene is presenting on March 26, 2025, from 11:30 AM to 11:50 AM Eastern Time at the Sheraton Boston Hotel, Track 2, Back Bay Ballroom AB.

What is the focus of Adagene's (ADAG) presentation at the IO360 Summit 2025?

The presentation focuses on ADG126 SAFEbody®, specifically targeting CTLA-4+ Tregs to overcome MSS CRC resistance in cancer treatment.

How can investors access Adagene's (ADAG) IO360 Summit presentation materials?

The presentation slides will be made available on the Presentations page of Adagene's company website following the event.

What is the significance of Adagene's (ADAG) participation in the 2025 IO360 Summit?

The summit provides Adagene an opportunity to showcase their immunotherapy developments to key stakeholders including pharma/biotech companies, academia, and investors in the cancer treatment field.